Skip to content Skip to footer
Subscribe Now
Viewpoints_Mark Genovese 
VIEWPOINTS

Lilly at UEGW 2024: Mark Genovese in an Illuminating Dialogue Exchange with PharmaShots shares insights into VIVID-1 study

Shots:  Recently, at UEGW 2024, Lilly presented histologic and combined histologic-endoscopic outcomes from the VIVID-1 Phase III study, which evaluated the safety and efficacy of mirikizumab in adults with moderately to severely active Crohn’s disease  A key finding reported during UEG Week highlighted the interactions between mirikizumab and ustekinumab, particularly regarding histologic response and remission,…
December 18, 2024

Read more

Viewpoints_Harmony Garges
VIEWPOINTS

ViiV at IDWeek 2024: Dr. Harmony Garges in an Illuminating Dialogue Exchange with PharmaShots

Shots:  Recently at IDWeek 2024, ViiV Healthcare presented data from two real-world studies on Apretude, a long-acting injectable (LAI) for HIV pre-exposure prophylaxis.  Dr. Harmony Garges, Chief Medical Officer at ViiV, shared insights from the presentations. The Opera cohort study found Apretude to be 99.7% effective in preventing HIV among participants. Additionally, the Trio Health…
December 16, 2024

Read more

Viewpoints_Dino Kazanis_James C. Swartz
VIEWPOINTS

Inspiring Innovations: Dino Kazanis and James Swartz in a Stimulating Conversation with PharmaShots

Shots:  Thermo Fisher Scientific has recently signed a distribution agreement with Labguru to accelerate research and drive scientific breakthroughs. This collaboration integrates Labguru’s state-of-the-art Electronic Lab Notebook (ELN) with Thermo Fisher Scientific’s comprehensive suite of Laboratory Information Management Systems (LIMS) and lab operations software solutions.  By combining ELN and LIMS tools, the partnership aims to…
December 11, 2024

Read more

Spotlight Interview_Cary Claiborne
SPOTLIGHT

CXO Talks: Cary Claiborne from Adial Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots

Welcome to the sixth episode of CXO Talks, featuring Cary Claiborne, CEO of Adial Pharmaceuticals a clinical-stage biopharmaceutical company dedicated to developing therapies for the treatment and prevention of addiction and related disorders.  Taking a walk down memory lane, Cary shares the inspiration behind founding Adial Pharmaceuticals. He recounts how an early study at the…
December 9, 2024

Read more

Viewpoints_Marcelo Freire
VIEWPOINTS

Takeda at UEG Week 2024: Marcelo Freire from Takeda in an Enlightening Conversation with PharmaShots

Shots:  Recently, Takeda shared 32-week interim results from the VERDICT study, which evaluated Entyvio (vedolizumab) for the treatment of patients with ulcerative colitis (UC)  Entyvio achieved a stringent endpoint of disease clearance, a new concept in UC clinical research, which is a combination of clinical, endoscopic, and histologic remission  Today at PharmaShots, we are joined…
December 2, 2024

Read more

Viewpoints_Richard Watts
VIEWPOINTS

Enhancing Diagnostic Care: Richard Watts from Qiagen in a Stimulating Conversation with PharmaShots

Shots:  Recently, Qiagen entered into a collaboration agreement with AstraZeneca to develop companion diagnostics for chronic diseases using Qiagen’s QIAstat-Dx system  Today, at PharmaShots, we are joined by Richard Watts from Qiagen, who sheds light on their collaboration agreements with AstraZeneca and Eli Lilly, leveraging their syndromic testing platform, QIAstat-Dx  Qiagen has partnered with over…
November 27, 2024

Read more

New Drug Designations - October 2024
INSIGHTS+

New Drug Designations – October 2024

Shots:   PharmaShots' designation report provides a concise overview of the latest drug designations by major regulatory authorities, including the FDA, NMPA, and EMA   The October 2024 report covers designations granted to 33 drugs and 2 devices, encompassing 14 small molecules, 4 biologics, 8 cell and gene therapies, and 2 medical devices.  Significant trends this month…
November 26, 2024

Read more

Viewpoints_John Santini
VIEWPOINTS

Fluorescence Visualization in Lung Cancer: John Santini from Vergent Bioscience in Conversation with PharmaShots

Shots:  With the growing significance of minimally invasive surgery comes the need for enhanced visualization to optimize surgical outcomes for both surgeons and patients.  Vergent BioScience’s VGT-309 shows promising potential for tumor visualization during lung cancer surgeries. VGT-309 is an investigational intraoperative molecular imaging (IMI) agent that utilizes near-infrared (NIR) fluorescence imaging to improve precision. …
November 25, 2024

Read more

Viewpoints_Phil Lambert
VIEWPOINTS

Enhancing DMD Care: Phil Lambert from Satellos in a Riveting Conversation with PharmaShots

Shots:  Conventional therapeutic models for Duchenne Muscular Dystrophy (DMD) primarily focus on the role of dystrophin in maintaining muscle cell integrity. However, Satellos’ SAT-3247 takes a novel approach, targeting the lack of dystrophin in muscle stem cells to restore muscle fiber regeneration and repair  Today at PharmaShots, we are joined by Phil Lambert, Chief Scientific…
November 20, 2024

Read more

Viewpoints_Samuel Gidding_Allison Jamison
VIEWPOINTS

Bringing Awareness to the Public: Samuel S. Gidding & Allison Jamison in an Enlightening Conversation with PharmaShots

Shots:  Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic condition that affects approximately 1 in 250,000 Americans. It is characterized by the presence of two genetic mutations that lead to extremely high levels of LDL cholesterol.  In this interview, Sam Gidding and Allison Jamison from the Family Heart Foundation/ emphasize the critical need for enhanced…
November 18, 2024

Read more

Load more